Ilaria Laurenzana

Dr. Ilaria Laurenzana

Lab of Preclinical and Translational Research, IRCCS CROB - Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
LLLuciana De Luca
Luciana De Luca
STStefania Trino
Stefania Trino
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
VSVittorio Simeon
Vittorio Simeon
GCGiovanni Calice
Giovanni Calice
PMPellegrino Musto
Pellegrino Musto
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation

Verified
Journal Article
Open access
PDF file
STStefania Trino
Stefania Trino
DLDaniela Lamorte
Daniela Lamorte
ACAntonella Caivano
Antonella Caivano
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
DTDaniela Tagliaferri
Daniela Tagliaferri
LLLuciana De Luca
Luciana De Luca
Acute myeloid leukemias (AML) are clonal disorders of hematopoietic progenitor cells which are characterized by relevant heterogeneity in terms of phenotypic, genotypic, and clinical features. Among the genetic aberrations that control disease development there are microRNAs (miRNAs). miRNAs are small non-coding RNAs that regulate, at post-transcriptional level, translation and stability of mRNAs. It is now established that deregulated miRNA expression is a prominent feature in AML. Functional studies have shown that miRNAs play an important role in AML pathogenesis and miRNA expression signatures are associated with chemotherapy response and clinical outcome. In this review we summarized miRNA signature in AML with different cytogenetic, molecular and clinical characteristics. Moreover, we reviewed the miRNA regulatory network in AML pathogenesis and we discussed the potential use of cellular and circulating miRNAs as biomarkers for diagnosis and prognosis and as therapeutic targets.

19 October 2016 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
ACAntonella Caivano
Antonella Caivano
FRFrancesco La Rocca
Francesco La Rocca
VSVittorio Simeon
Vittorio Simeon
MGMarco Girasole
Marco Girasole
SDSimone Dinarelli
Simone Dinarelli
PMPellegrino Musto
Pellegrino Musto

9 December 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
STStefania Trino
Stefania Trino
DLDaniela Lamorte
Daniela Lamorte
ACAntonella Caivano
Antonella Caivano
LLLuciana De Luca
Luciana De Luca
ASAlessandro Sgambato
Alessandro Sgambato
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
In the era of precision medicine, liquid biopsy is becoming increasingly important in oncology. It consists in the isolation and analysis of tumor-derived biomarkers, including extracellular vesicles (EVs), in body fluids. EVs are lipid bilayer-enclosed particles, heterogeneous in size and molecular composition, released from both normal and neoplastic cells. In tumor context, EVs are valuable carriers of cancer information; in fact, their amount, phenotype and molecular cargo, including proteins, lipids, metabolites and nucleic acids, mirror nature and origin of parental cells rendering EVs appealing candidates as novel biomarkers. Translation of these new potential diagnostic tools into clinical practice could deeply revolutionize the cancer field mainly for solid tumors but for hematological neoplasms, too.

18 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
TTTiziana Tataranni
Tiziana Tataranni
FAFrancesca Agriesti
Francesca Agriesti
CPConsiglia Pacelli
Consiglia Pacelli
VRVitalba Ruggieri
Vitalba Ruggieri
Ilaria LaurenzanaIlaria Laurenzana
Ilaria Laurenzana
CPClaudia Piccoli
Claudia Piccoli
Targeting metabolism represents a possible successful approach to treat cancer. Dichloroacetate (DCA) is a drug known to divert metabolism from anaerobic glycolysis to mitochondrial oxidative phosphorylation by stimulation of PDH. In this study, we investigated the response of two pancreatic cancer cell lines to DCA, in two-dimensional and three-dimension cell cultures, as well as in a mouse model. PANC-1 and BXPC-3 treated with DCA showed a marked decrease in cell proliferation and migration which did not correlate with enhanced apoptosis indicating a cytostatic rather than a cytotoxic effect. Despite PDH activation, DCA treatment resulted in reduced mitochondrial oxygen consumption without affecting glycolysis. Moreover, DCA caused enhancement of ROS production, mtDNA, and of the mitophagy-marker LC3B-II in both cell lines but reduced mitochondrial fusion markers only in BXPC-3. Notably, DCA downregulated the expression of the cancer stem cells markers CD24/CD44/EPCAM only in PANC-1 but inhibited spheroid formation/viability in both cell lines. In a xenograft pancreatic cancer mouse-model DCA treatment resulted in retarding cancer progression. Collectively, our results clearly indicate that the efficacy of DCA in inhibiting cancer growth mechanistically depends on the cell phenotype and on multiple off-target pathways. In this context, the novelty that DCA might affect the cancer stem cell compartment is therapeutically relevant.